Literature DB >> 25367220

A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.

Brian G Blair1, Xinyan Wu, Muhammad Saddiq Zahari, Morassa Mohseni, Justin Cidado, Hong Yuen Wong, Julia A Beaver, Rory L Cochran, Daniel J Zabransky, Sarah Croessmann, David Chu, Patricia Valda Toro, Karen Cravero, Akhilesh Pandey, Ben Ho Park.   

Abstract

The PIK3CA gene encodes for the p110 alpha isoform of PI3 kinase and is one of the most frequently mutated oncogenes in human cancers. However, the mechanisms by which PIK3CA mutations activate cell signaling are not fully understood. Here we used a phosphoproteomic approach to compare differential phosphorylation patterns between human breast epithelial cells and two isogenic somatic cell knock in derivatives, each harboring a distinct PIK3CA mutation. We demonstrated differential phosphorylation patterns between isogenic cell lines containing a PIK3CA helical domain mutation (E545K) compared to cells with a PIK3CA kinase domain mutation (H1047R). In particular, the receptor tyrosine kinase, HER3, showed increased phosphorylation at tyrosine 1328 in H1047R cells versus E545K cells. Genetic studies using shRNA demonstrated that H1047R cells have a profound decrease in growth factor independent proliferation upon HER3 knock down, but this effect was attenuated in E545K cells. In addition, HER3 knock down led to reductions in both PI3 kinase and MAP kinase pathway activation in H1047R cells, but in E545K cells only PI3 kinase pathway diminution was observed. These studies demonstrate the power of using paired isogenic cell lines for proteomic analysis to gain new insights into oncogenic signal transduction pathways.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Biomedicine; HER3; MAP kinase; PI3 kinase; PIK3CA

Mesh:

Substances:

Year:  2014        PMID: 25367220      PMCID: PMC4352327          DOI: 10.1002/pmic.201400342

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  24 in total

1.  Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10.

Authors:  H D Soule; T M Maloney; S R Wolman; W D Peterson; R Brenz; C M McGrath; J Russo; R J Pauley; R F Jones; S C Brooks
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

2.  The consensus coding sequences of human breast and colorectal cancers.

Authors:  Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Science       Date:  2006-09-07       Impact factor: 47.728

3.  Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.

Authors:  Hiroyuki Konishi; Bedri Karakas; Abde M Abukhdeir; Josh Lauring; John P Gustin; Joseph P Garay; Yuko Konishi; Eike Gallmeier; Kurtis E Bachman; Ben Ho Park
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

4.  The PIK3CA gene is mutated with high frequency in human breast cancers.

Authors:  Kurtis E Bachman; Pedram Argani; Yardena Samuels; Natalie Silliman; Janine Ptak; Steve Szabo; Hiroyuki Konishi; Bedri Karakas; Brian G Blair; Clarence Lin; Brock A Peters; Victor E Velculescu; Ben Ho Park
Journal:  Cancer Biol Ther       Date:  2004-08-26       Impact factor: 4.742

5.  Tamoxifen-stimulated growth of breast cancer due to p21 loss.

Authors:  Abde M Abukhdeir; Michele I Vitolo; Pedram Argani; Angelo M De Marzo; Bedri Karakas; Hiroyuki Konishi; John P Gustin; Josh Lauring; Joseph P Garay; Courtney Pendleton; Yuko Konishi; Brian G Blair; Keith Brenner; Elizabeth Garrett-Mayer; Hetty Carraway; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-27       Impact factor: 11.205

6.  The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.

Authors:  Chuan-Hsiang Huang; Diana Mandelker; Oleg Schmidt-Kittler; Yardena Samuels; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Sandra B Gabelli; L Mario Amzel
Journal:  Science       Date:  2007-12-14       Impact factor: 47.728

7.  The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

Authors:  Josh Lauring; Abde M Abukhdeir; Hiroyuki Konishi; Joseph P Garay; John P Gustin; Qiuju Wang; Robert J Arceci; William Matsui; Ben Ho Park
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

8.  Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.

Authors:  Li Zhao; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-11       Impact factor: 11.205

9.  Knockin of mutant PIK3CA activates multiple oncogenic pathways.

Authors:  John P Gustin; Bedri Karakas; Michele B Weiss; Abde M Abukhdeir; Josh Lauring; Joseph P Garay; David Cosgrove; Akina Tamaki; Hiroyuki Konishi; Yuko Konishi; Morassa Mohseni; Grace Wang; D Marc Rosen; Samuel R Denmeade; Michaela J Higgins; Michele I Vitolo; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

10.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nucleic Acids Res       Date:  2008-11-25       Impact factor: 16.971

View more
  7 in total

Review 1.  Targeting Signaling Transduction Pathways in Bladder Cancer.

Authors:  Phillip H Abbosh; David J McConkey; Elizabeth R Plimack
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

2.  PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity.

Authors:  Sarah Croessmann; Hong Yuen Wong; Daniel J Zabransky; David Chu; D Marc Rosen; Justin Cidado; Rory L Cochran; W Brian Dalton; Bracha Erlanger; Karen Cravero; Berry Button; Kelly Kyker-Snowman; Paula J Hurley; Josh Lauring; Ben Ho Park
Journal:  Breast Cancer Res Treat       Date:  2017-02-11       Impact factor: 4.872

Review 3.  Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.

Authors:  M J Alvarez-Cubero; L J Martinez-Gonzalez; I Robles-Fernandez; J Martinez-Herrera; G Garcia-Rodriguez; M Pascual-Geler; J M Cozar; J A Lorente
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

4.  HER2 missense mutations have distinct effects on oncogenic signaling and migration.

Authors:  Daniel J Zabransky; Christopher L Yankaskas; Rory L Cochran; Hong Yuen Wong; Sarah Croessmann; David Chu; Shyam M Kavuri; Monica Red Brewer; D Marc Rosen; W Brian Dalton; Ashley Cimino-Mathews; Karen Cravero; Berry Button; Kelly Kyker-Snowman; Justin Cidado; Bracha Erlanger; Heather A Parsons; Kristen M Manto; Ron Bose; Josh Lauring; Carlos L Arteaga; Konstantinos Konstantopoulos; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-27       Impact factor: 11.205

Review 5.  Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.

Authors:  Libero Santarpia; Giulia Bottai; Catherine M Kelly; Balázs Győrffy; Borbala Székely; Lajos Pusztai
Journal:  Oncologist       Date:  2016-07-06

6.  Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.

Authors:  Sanja B Turturro; Matthew S Najor; Carl E Ruby; Melody A Cobleigh; Abde M Abukhdeir
Journal:  Breast Cancer Res Treat       Date:  2016-02-25       Impact factor: 4.872

7.  Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases.

Authors:  Malcolm Lim; Tam H Nguyen; Colleen Niland; Lynne E Reid; Parmjit S Jat; Jodi M Saunus; Sunil R Lakhani
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.